Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Stohrer 2003 LAO (Continued)<br />
Allocation concealment? Unclear ’A sealed envelope was opened which assigned<br />
patients to one of the two treatment<br />
arms’. No further details given.<br />
Blinding?<br />
All outcomes<br />
Incomplete outcome data addressed?<br />
All outcomes<br />
No An open label trial. No comment on blinding<br />
of laboratory staff, quality control was<br />
conducted by rechecking malaria films by<br />
expert microscopists.<br />
Yes Disproportionate losses to follow up<br />
(11.3% AL6 vs 3.6% AS+MQ) but unlikely<br />
to have affected the overall result<br />
Free of selective reporting? Yes <strong>The</strong> WHO recommends 63 days follow up<br />
in studies of AS+MQ. Day 42 outcomes<br />
may overestimate the efficacy of AS+MQ.<br />
Free of other bias? Yes No other sources of bias identified<br />
Swarthout 2004 ZAR<br />
Methods Trial design: An open label randomized controlled trial<br />
Follow up: Examination and malaria film on days 0, 1, 2, 3, 7, 14, 21, and 28, or other<br />
times if they were unwell<br />
Adverse event monitoring: Parents and guardians were asked about tolerability and potential<br />
side effects of the drugs<br />
Participants Number: 180 randomized<br />
Inclusion criteria: Age 6 to 59 months, symptoms suggestive of malaria, P. falciparum<br />
mono-infection 2000 to 200,000/µl, able to take the study drugs orally, able to attend<br />
follow up, in<strong>for</strong>med consent<br />
Exclusion criteria: Severe or complicated malaria, concomitant disease that could mask<br />
response to antimalarial treatment, known hypersensitivity to any of the study drugs<br />
Interventions 1. Artesunate plus amodiaquine<br />
• No dosing details given<br />
2. Artesunate plus sulfadoxine-pyrimethamine<br />
• No dosing details given<br />
All doses supervized<br />
Outcomes 1. Failure rate at day 28, PCR adjusted and unadjusted<br />
2. Gametocytaemia during follow up<br />
3. <strong>The</strong> percentage of participants with mild and moderate anaemia during follow up<br />
4. Adverse events<br />
Not included in the review:<br />
1. Fever clearance<br />
2. Parasite clearance<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
92